Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject for the third-phase clinical trial of biologic drug T-Bren for injection, according to a weekend filing with the Shanghai bourse.
The trial evaluates T-Bren combined with pertuzumab versus standard chemotherapy in neoadjuvant treatment of HER2-positive breast cancer, according to a weekend filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 4% in recent trade.
Shui On Land (HKG:0272) said a company in which it holds a 19.8% stake agreed to sell a property in China to Chongqing Shengjuge Real Estate Agency for 201 million yuan.Chongqing Shui On Tiandi Real Estate Development expects the sale of the commercial site with a gross floor area of 31,287 square meters to support its resource allocation and cash flow, according to a Tuesday filing in Hong Kong.
Lisi Group (HKG:0526) unit Ningbo Lisi Household Products renewed the lease of a factory space and office property in China ahead of its Sept. 30 expiry.The new lease agreement signed with lessor Da Mei (Ningbo) New Materials will be effective for three years starting Oct. 1, 2026, and ending Sept. 30, 2029.
Hunlicar Group (HKG:3638) named CEO Chan Wing Sum as its acting chairman effective Friday, according to a same-day bourse filing.